Type 2 Diabetes Management Guidelines

First-Line Therapy

The American College of Physicians recommends starting all patients with metformin (unless contraindicated) plus lifestyle modifications, then add an SGLT-2 inhibitor or GLP-1 agonist when glycemic control remains inadequate 1, 2, 3, 4
Metformin remains the mandatory first-line pharmacologic therapy for type 2 diabetes, with lifestyle modifications including 30 minutes of physical activity at least five times weekly, calorie restriction to 1500 kcal/day, and limiting fat to 30-35% of total energy intake 5
Lifestyle interventions alone can decrease HbA1c by approximately 2% and produce 5 kg weight loss 5

Prioritize SGLT-2 inhibitors when the patient has congestive heart failure, chronic kidney disease, or the primary goal is reducing cardiovascular mortality, hospitalization for heart failure, or preventing progression of kidney disease 1, 2, 3, 4, 5, 6, 7
Prioritize GLP-1 agonists when the patient has increased stroke risk, total body weight loss is an important treatment goal, or the patient needs all-cause mortality reduction without heart failure or CKD 1, 2, 3, 4, 5, 6, 7

Target HbA1c between 7% and 8% for most adults with type 2 diabetes, with individualized targets based on hypoglycemia risk, life expectancy, diabetes duration, established vascular complications, and major comorbidities 1, 2, 3, 4, 5, 6, 7
Deintensify pharmacologic treatments when HbA1c falls below 6.5% to avoid hypoglycemia and overtreatment 1, 2, 3, 4, 5, 6, 7

When SGLT-2 inhibitors or GLP-1 agonists achieve adequate glycemic control, reduce or discontinue sulfonylureas or long-acting insulins immediately due to severe hypoglycemia risk 1, 2, 3, 4, 5, 6, 7
Sulfonylureas and long-acting insulins are inferior to SGLT-2 inhibitors and GLP-1 agonists for reducing all-cause mortality and morbidity 1, 2, 3, 4, 5, 6

Do not add DPP-4 inhibitors to metformin—they fail to reduce morbidity or all-cause mortality, as recommended by the American College of Physicians with high-certainty evidence 1, 2, 3, 4, 6

Patients with diabetes and chronic kidney disease require a multi-pronged approach beyond glycemic control, including RAS blockade, statin therapy, and consideration of nonsteroidal mineralocorticoid receptor antagonist 8
Limit sodium intake to 2,300 mg/day 9

For patients on insulin secretagogues, eat moderate amounts of carbohydrate at each meal and snacks, and never skip meals to reduce hypoglycemia risk 9
For patients on metformin, take medication with food or 15 minutes after a meal if gastrointestinal symptoms persist, and gradually titrate dose to minimize gastrointestinal side effects 9

Use 15-20 g of glucose tablets or carbohydrate-containing foods to treat hypoglycemia, and recheck blood glucose 15-20 minutes after treatment; repeat if hypoglycemia persists 9

No generic SGLT-2 inhibitors or GLP-1 agonists currently exist; discuss medication costs with patients when selecting specific agents 1, 2, 3, 4, 5, 6
Prescribe generic medications when available rather than brand-name alternatives 1, 2, 3, 4, 5

Involve clinical pharmacists in medication management to reduce polypharmacy risks, and address sleep health, stress management, and all comorbidities as part of integrated care plans 1, 2, 3, 4, 5, 6
Use collaborative communication and goal-setting among all team members 1, 2, 3, 4, 5, 6